By Mill Chart
Last update: Nov 14, 2023
In this article we will dive into ALKERMES PLC (NASDAQ:ALKS) as a possible candidate for growth investing. Investors should always do their own research, but we noticed ALKERMES PLC showing up in our strong growth, ready to breakout screen, which makes it worth to investigate a bit more.
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:ALKS, the assigned 8 reflects its growth potential:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:ALKS has received a 6 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:ALKS was assigned a score of 6 for profitability:
In addition to the Technical Rating, ChartMill provides a Setup Rating for each stock. This rating, ranging from 0 to 10, assesses the level of consolidation in the stock based on multiple short-term technical indicators. Currently, NASDAQ:ALKS has a 7 as its setup rating, indicating its current consolidation status.
Although the technical rating is bad, ALKS does present a nice setup opportunity. We see reduced volatility while prices have been consolidating in the most recent period. There is a support zone below the current price at 23.80, a Stop Loss order could be placed below this zone.
Our Strong Growth screener lists more Strong Growth stocks and is updated daily.
Our latest full fundamental report of ALKS contains the most current fundamental analsysis.
For an up to date full technical analysis you can check the technical report of ALKS
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
ALKERMES PLC
NASDAQ:ALKS (4/26/2024, 7:00:00 PM)
After market: 24.68 0 (0%)24.68
+0.24 (+0.98%)
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.